191 related articles for article (PubMed ID: 31761151)
1. A case of fixed drug eruption induced by doxycycline, mimicking a symmetrical drug-related intertriginous and flexural exanthema (SDRIFE).
Favrelière S; Hosteing S; Jazeron JF; Allouchery M; Lafay-Chebassier C; Perault-Pochat MC
Therapie; 2020; 75(5):511-513. PubMed ID: 31761151
[No Abstract] [Full Text] [Related]
2. Co-occurrence of Symmetrical Drug-Related Intertriginous and Flexural Exanthema (SDRIFE) and Pigmented Fixed Drug Eruption (FDE) in a Single Patient Due to Doxycycline: A Case Report.
Sahu K; Sirka CS; Pradhan S; Rout AN
Indian Dermatol Online J; 2020; 11(1):62-64. PubMed ID: 32055511
[TBL] [Abstract][Full Text] [Related]
3. Symmetrical drug related intertriginous and flexural exanthema (SDRIFE) induced by fluconazole: An uncommon side effect of a commonly used drug.
Kumar S; Bhale G; Brar BK
Dermatol Ther; 2019 Nov; 32(6):e13130. PubMed ID: 31659833
[No Abstract] [Full Text] [Related]
4. Rare case of itraconazole induced SDRIFE (symmetrical drug-related intertriginous and flexural exanthema).
Koschitzki K; Karrer S; Berneburg M; Niebel D; Drexler K
J Dtsch Dermatol Ges; 2024 Jun; 22(6):833-836. PubMed ID: 38567643
[No Abstract] [Full Text] [Related]
5. Remdesivir-induced symmetrical drug-related intertriginous and flexural exanthema (SDRIFE)? A case report with review of the literature.
Heck J; Stichtenoth DO; Mettin R; Jöckel J; Bickel C; Krichevsky B
Eur J Clin Pharmacol; 2021 Jan; 77(1):141-144. PubMed ID: 32761371
[No Abstract] [Full Text] [Related]
6. Symmetrical Drug-Related Intertriginous and Flexural Exanthema (SDRIFE) Caused by Etoricoxib.
Caralli ME; Seoane Rodríguez M; Rojas Pérez-Ezquerra P; Pelta Fernández R; De Barrio Fernández M
J Investig Allergol Clin Immunol; 2016; 26(2):128-9. PubMed ID: 27164635
[No Abstract] [Full Text] [Related]
7. Itraconazole-induced symmetrical drug-related intertriginous and flexural exanthema (SDRIFE): a rare occurrence.
Kalita BJ; Das S; Dutta B
Int J Dermatol; 2020 Nov; 59(11):e419-e421. PubMed ID: 32767394
[No Abstract] [Full Text] [Related]
8. Three cases of symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) induced by proton-pump inhibitors.
Spigariolo CB; Barei F; Maronese CA; Barberi F; Cattaneo A; Violetti SA
Australas J Dermatol; 2022 Nov; 63(4):509-512. PubMed ID: 35877187
[TBL] [Abstract][Full Text] [Related]
9. Zoledronic acid-induced symmetrical drug-related intertriginous and flexural exanthema (SDRIFE).
Kandala H; Gonzalez-Mosquera LF; Barua P; Podrumar A
BMJ Case Rep; 2021 Sep; 14(9):. PubMed ID: 34518192
[No Abstract] [Full Text] [Related]
10. A challenging case: Symmetrical drug related intertriginous and flexural exanthem, fixed drug eruption, or both?
Özkaya E; Babuna G
Pediatr Dermatol; 2011; 28(6):711-714. PubMed ID: 22082466
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide-induced symmetrical drug-related intertriginous and flexural exanthema.
Patel RT; Quan EY; Eikenberg JD; Grider DJ; Phillips MA
Dermatol Online J; 2023 Aug; 29(4):. PubMed ID: 37921816
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel-induced symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) confirmed by skin testing.
Hampel A; Kinaciyan T
Contact Dermatitis; 2024 May; 90(5):525-527. PubMed ID: 38263696
[No Abstract] [Full Text] [Related]
13. A case of symmetrical drug-related intertriginous and flexural exanthema-like eruption associated with Pfizer COVID-19 vaccination.
Manaa A; Ziv M; Krausz J; Dodiuk-Gad RP
Dermatol Ther; 2022 Jul; 35(7):e15546. PubMed ID: 35485220
[No Abstract] [Full Text] [Related]
14. Symmetrical drug-related intertriginous and flexural exanthema with high-risk systemic features: a unique clinical phenotype in hospitalized patients.
Kirven RM; Fisher K; Kaffenberger BH; Chung CG; Korman AM
Arch Dermatol Res; 2024 May; 316(6):279. PubMed ID: 38796524
[TBL] [Abstract][Full Text] [Related]
15. A systematic approach to systemic contact dermatitis and symmetric drug-related intertriginous and flexural exanthema (SDRIFE): a closer look at these conditions and an approach to intertriginous eruptions.
Winnicki M; Shear NH
Am J Clin Dermatol; 2011 Jun; 12(3):171-80. PubMed ID: 21469762
[TBL] [Abstract][Full Text] [Related]
16. Symmetrical drug-related intertriginous and flexural exanthema due to ranitidine.
Binitha MP; Sasidharanpillai S; John R; Sherjeena PV
Indian J Pharmacol; 2014; 46(5):551-2. PubMed ID: 25298589
[TBL] [Abstract][Full Text] [Related]
17. Symmetrical drug-related intertriginous and flexural exanthema/baboon syndrome induced by traditional Chinese medicine.
Liu J; Li LF
J Cosmet Dermatol; 2022 May; 21(5):2200-2204. PubMed ID: 34333850
[TBL] [Abstract][Full Text] [Related]
18. Paracetamol-induced symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) in a psoriasis patient receiving apremilast therapy.
Megna M; Cinelli E; Napolitano M; Fabbrocini G; Patruno C
Contact Dermatitis; 2019 Dec; 81(6):451-454. PubMed ID: 31328275
[No Abstract] [Full Text] [Related]
19. Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) induced by oral metronidazole.
Şikar Aktürk A; Bayramgürler D; Salman S; Yıldız KD; Odyakmaz Demirsoy E
Cutan Ocul Toxicol; 2014 Dec; 33(4):337-8. PubMed ID: 24938451
[TBL] [Abstract][Full Text] [Related]
20. Reply to "A case of symmetrical drug-related intertriginous and flexural exanthema-like eruption associated with Pfizer COVID-19 vaccination" by Manaa et al.
Camela E; Scalvenzi M; Megna M; Potestio L; Guerrasio G; Fornaro L; Fabbrocini G; Costa C
Dermatol Ther; 2022 Dec; 35(12):e15881. PubMed ID: 36181410
[No Abstract] [Full Text] [Related]
[Next] [New Search]
